These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 20179198)

  • 1. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.
    Creighton CJ; Fountain MD; Yu Z; Nagaraja AK; Zhu H; Khan M; Olokpa E; Zariff A; Gunaratne PH; Matzuk MM; Anderson ML
    Cancer Res; 2010 Mar; 70(5):1906-15. PubMed ID: 20179198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues].
    Zhang Q; He XJ; Ma LP; Li N; Yang J; Cheng YX; Cui H
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):885-90. PubMed ID: 22340095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer.
    Amir S; Ma AH; Shi XB; Xue L; Kung HJ; Devere White RW
    PLoS One; 2013; 8(4):e61064. PubMed ID: 23585871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
    Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
    BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner.
    Wang Y; Qiu C; Lu N; Liu Z; Jin C; Sun C; Bu H; Yu H; Dongol S; Kong B
    Int J Oncol; 2018 Jun; 52(6):2130-2142. PubMed ID: 29620165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines.
    Park YB; Park MJ; Kimura K; Shimizu K; Lee SH; Yokota J
    Cancer Genet Cytogenet; 2002 Mar; 133(2):105-11. PubMed ID: 11943335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
    Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
    BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional analysis of miR-34c as a putative tumor suppressor in high-grade serous ovarian cancer.
    Yu Z; Kim J; He L; Creighton CJ; Gunaratne PH; Hawkins SM; Matzuk MM
    Biol Reprod; 2014 Nov; 91(5):113. PubMed ID: 25273528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis.
    Hemmati PG; Gillissen B; von Haefen C; Wendt J; Stärck L; Güner D; Dörken B; Daniel PT
    Oncogene; 2002 May; 21(20):3149-61. PubMed ID: 12082630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.
    Lee CH; Subramanian S; Beck AH; Espinosa I; Senz J; Zhu SX; Huntsman D; van de Rijn M; Gilks CB
    PLoS One; 2009 Oct; 4(10):e7314. PubMed ID: 19798417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
    Lee H; Park CS; Deftereos G; Morihara J; Stern JE; Hawes SE; Swisher E; Kiviat NB; Feng Q
    World J Surg Oncol; 2012 Aug; 10():174. PubMed ID: 22925189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 13. Expression of Interactive Genes Associated with Apoptosis and Their Prognostic Value for Ovarian Serous Adenocarcinoma.
    Shin K; Kim KH; Yoon MS; Suh DS; Lee JY; Kim A; Eo W
    Adv Clin Exp Med; 2016; 25(3):513-21. PubMed ID: 27629740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.
    Mullany LK; Fan HY; Liu Z; White LD; Marshall A; Gunaratne P; Anderson ML; Creighton CJ; Xin L; Deavers M; Wong KK; Richards JS
    Oncogene; 2011 Aug; 30(32):3522-36. PubMed ID: 21423204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma.
    Zhou J; Gong G; Tan H; Dai F; Zhu X; Chen Y; Wang J; Liu Y; Chen P; Wu X; Wen J
    Oncol Rep; 2015 Jun; 33(6):2915-23. PubMed ID: 25962395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma.
    Dong R; Liu X; Zhang Q; Jiang Z; Li Y; Wei Y; Li Y; Yang Q; Liu J; Wei JJ; Shao C; Liu Z; Kong B
    Oncotarget; 2014 Nov; 5(21):10816-29. PubMed ID: 25333261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue.
    Nam EJ; Kim S; Lee TS; Kim HJ; Lee JY; Kim SW; Kim JH; Kim YT
    Oncotarget; 2016 Oct; 7(43):70524-70534. PubMed ID: 27655640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern.
    Lee SH; Kim H; Kim WY; Han HS; Lim SD; Kim WS; Kim S; Hwang TS
    Pathol Int; 2013 May; 63(5):252-9. PubMed ID: 23714252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miRNA-301b-3p accelerates migration and invasion of high-grade ovarian serous tumor via targeting CPEB3/EGFR axis.
    Liu F; Zhang G; Lv S; Wen X; Liu P
    J Cell Biochem; 2019 Aug; 120(8):12618-12627. PubMed ID: 30834603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.